Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity

Journal of Pineal Research

Volumn 57, Issue 3, 2014, Pages 317-332

  Nduhirabandi, Frederic ^a   Huisamen, Barbara ^a   Strijdom, Hans ^a   Blackhurst, Dee ^b   Lochner, Amanda ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

cardioprotection; insulin resistance; intracellular signalling; melatonin; myocardial ischaemia reperfusion injury; obesity

Indexed keywords

ADIPONECTIN; DRINKING WATER; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STAT3 PROTEIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; DIET INDUCED OBESITY; DIET RESTRICTION; ENZYME ACTIVATION; EX VIVO STUDY; EXPERIMENTAL MYOCARDIAL ISCHEMIA; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION SIZE; HEART OUTPUT; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISOLATED HEART; MALE; METABOLIC PARAMETERS; NONHUMAN; RAT; REPERFUSION INJURY; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; DRUG EFFECTS; HEART; INTRAABDOMINAL FAT; OBESITY; PATHOPHYSIOLOGY;

ANIMALS; BODY WEIGHT; HEART; INTRA-ABDOMINAL FAT; MELATONIN; OBESITY; RATS;

EID: 84925337999     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12171     Document Type: Article

References (71)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2095-2128.
2. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 7 million participants. Lancet 2011; 378: 31-40.
3. Murphy NF, Macintyre K, Stewart S, et al. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006; 27: 96-106.
4. Reiter RJ, Tan DX, Korkmaz A, et al. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2012; 44: 564-577.
5. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. Circulation 2009; 120: 1640-1645.
6. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 2006; 113: 898-918.
7. Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008; 19: 491-504.
8. Otani H,. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011; 15: 1911-1926.
9. Rizvi AA,. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 2009; 338: 310-318.
10. Boden G,. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011; 18: 139-143.
11. Nduhirabandi F, du Toit EF, Lochner A,. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf) 2012; 205: 209-223.
12. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia MJ, et al. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002; 33: 248-252.
13. Lochner A, Huisamen B, Nduhirabandi F,. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. Front Biosci (Elite Ed) 2013; 5: 305-315.
14. Lochner A, Genade S, Davids A, et al. Short- and long-term effects of melatonin on myocardial post-ischemic recovery. J Pineal Res 2006; 40: 56-63.
15. Nduhirabandi F, du Toit EF, Blackhurst D, et al. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res 2011; 50: 171-182.
16. Agil A, Reiter RJ, Jimenez-Aranda A, et al. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J Pineal Res 2013; 54: 381-388.
17. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
18. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
19. Tamareille S, Mateus V, Ghaboura N, et al. RISK and SAFE signalling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 2011; 106: 1329-1339.
20. Lecour S,. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40.
21. Lamont KT, Somers S, Lacerda L, et al. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 2011; 50: 374-380.
22. du Toit EF, Smith W, Muller C, et al. Myocardial susceptibility to ischemic-reperfusion injury in a prediabetic model of dietary-induced obesity. Am J Physiol Heart Circ Physiol 2008; 294: H2336-H2343.
23. Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
24. Prunet-Marcassus B, Desbazeille M, Bros A, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003; 144: 5347-5352.
25. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
26. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
27. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
28. Hui X, Lam KS, Vanhoutte PM, et al. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012; 165: 574-590.
29. Persson J, Lindberg K, Gustafsson TP, et al. Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med 2010; 268: 194-205.
30. Cardinali DP, Bernasconi PA, Reynoso R, et al. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. Int J Mol Sci 2013; 14: 2502-2514.
31. Agil A, Navarro-Alarcon M, Ruiz R, et al. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res 2011; 50: 207-212.
32. Agil A, Rosado I, Ruiz R, et al. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2012; 52: 203-210.
33. Zanuto R, Siqueira-Filho MA, Caperuto LC, et al. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. J Pineal Res 2013; 55: 156-165.
34. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009; 150: 5311-5317.
35. Nishida S, Sato R, Murai I, et al. Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. J Pineal Res 2003; 35: 251-256.
36. Carvalheira JB, Siloto RM, Ignacchitti I, et al. Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett 2001; 500: 119-124.
37. Anhe GF, Caperuto LC, Pereira-Da-silva M, et al. In vivo activation of insulin receptor tyrosine kinase by melatonin in the rat hypothalamus. J Neurochem 2004; 90: 559-566.
38. Picinato MC, Hirata AE, Cipolla-Neto J, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res 2008; 44: 88-94.
39. Yang W, Lee W, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
40. Kitagawa A, Ohta Y, Ohashi K,. Melatonin improves metabolic syndrome induced by high fructose intake in rats. J Pineal Res 2012; 52: 403-413.
41. Ye R, Scherer PE,. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2: 133-141.
42. Tan DX, Manchester LC, Fuentesbroto L, et al. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011; 12: 167-188.
43. Jimenez-Aranda A, Fernández-Vázquez G, Campos D, et al. Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res 2013; 55: 416-423.
44. Bartness TJ, Demas GE, Song CK,. Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp Biol Med (Maywood) 2002; 227: 363-376.
45. Vincent HK, Taylor AG,. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006; 30: 400-418.
46. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
47. Hoyos M, Guerrero JM, Perez-Cano R, et al. Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res 2000; 28: 150-155.
48. Nishida S, Segawa T, Murai I, et al. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32: 26-33.
49. Bonnefont-Rousselot D, Guilloz V, Lepage S, et al. Protection of endogenous β-carotene in LDL oxidized by oxygen free radicals in the presence of supraphysiological concentrations of melatonin. Redox Rep 2003; 8: 95-104.
50. Radogna F, Paternoster L, de Nicola M, et al. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicol Appl Pharmacol 2009; 239: 37-45.
51. Guney Ş, Cumaoʇlu A, Öztürk G, et al. Comparison of melatonin effect on oxidant status and antioxidant capacity in liver and heart of young and aged rats. Int J Gerontol 2013; 7: 45-49.
52. Miki T, Itoh T, Sunaga D, et al. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012; 11: 67.
53. Whittington HJ, Babu GG, Mocanu MM, et al. The diabetic heart: too sweet for its own good? Cardiol Res Pract 2012; 2012: 845698.
54. Donner D, Headrick JP, Peart JN, et al. Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats. Dis Model Mech 2013; 6: 457-466.
55. Thakker GD, Frangogiannis NG, Zymek PT, et al. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring) 2008; 16: 2593-2600.
56. Katakam PVG, Jordan JE, Snipes JA, et al. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol 2007; 292: R920-R926.
57. Ansley DM, Wang B,. Oxidative stress and myocardial injury in the diabetic heart. J Pathol 2013; 229: 232-241.
58. Harmancey R, Vasquez HG, Guthrie PH, et al. Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart. FASEB J 2013; 27: 3966-3978.
59. Diez ER, Renna NF, Prado NJ, et al. Melatonin, given at the time of reperfusion, prevents ventricular arrhythmias in isolated hearts from fructose-fed rats and spontaneously hypertensive rats. J Pineal Res 2013; 55: 166-173.
60. Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16-25.
61. Genade S, Genis A, Ytrehus K, et al. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. J Pineal Res 2008; 45: 449-458.
62. Patel V, Upaganlawar A, Zalawadia R, et al. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol 2010; 644: 160-168.
63. Sallinen P, Manttari S, Leskinen H, et al. The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res 2007; 42: 254-260.
64. Hausenloy DJ, Tsang A, Yellon DM,. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
65. Petrosillo G, Colantuono G, Moro N, et al. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol 2009; 297: H1487-H1493.
66. Juhaszova M, Zorov DB, Yaniv Y, et al. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104: 1240-1252.
67. Wensley I, Salaveria K, Bulmer AC, et al. Myocardial structure, function, and ischaemic tolerance in a rodent model of obesity with insulin resistance. Exp Physiol 2013; 98: 1552-1564.
68. Zgheib C, Zouein FA, Kurdi M, et al. Differential STAT3 signaling in the heart: impact of concurrent signals and oxidative stress. JAK-STAT 2012; 1: 101-110.
69. Zouein FA, Kurdi MM, Booz GW,. Dancing rhinos in stilettos: the amazing saga of the genomic and nongenomic actions of STAT3 in the heart. JAK-STAT 2013; 2: e24352.
70. Yang Y, Duan W, Jin Z, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res 2013; 55: 275-286.
71. Smith CC, Dixon RA, Wynne AM, et al. Leptin-induced cardioprotection involves JAK/STAT signalling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010; 299: H1265-H1270.